Tag

Novo Nordisk

All articles tagged with #novo nordisk

health-and-science8 days ago•3 min saved

Amylin and Triple-Agonist Trials Signal Next Wave in Obesity Treatment

Eli Lilly and Novo Nordisk are advancing next-generation obesity treatments targeting the amylin pathway and multiple hormone receptors. Lilly’s Phase 2 trial showed its amylin drug eloralintide, combined with tirzepatide, achieved 23.3% weight loss, though side effects caused higher discontinuation rates. Meanwhile, Lilly’s triple-agonist retatrutide reached a Phase 3 milestone, with 12mg doses yielding 18.8% weight loss and improved metabolic markers in diabetic patients. Novo is preparing to launch its amylin-based CagriSema next year. These developments aim to address patients who do not respond adequately to current GLP-1 therapies, expanding treatment options through multi-pathway approaches.

via CNBC|

#amylin #eli-lilly #health-and-science

health-and-legal9 days ago•63 min saved

Massachusetts Father’s Blindness Lawsuit Highlights Growing GLP-1 Vision Disputes

Edward Gillen, a Massachusetts father and former state highway worker, has joined a wave of over 200 lawsuits alleging that GLP-1 drugs like Ozempic caused permanent blindness. He claims the medication led to non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition described as a 'stroke' of the optic nerve. While Gillen and other plaintiffs argue that manufacturers failed to warn about this risk, Novo Nordisk maintains that the drug has a strong safety profile and that the lawsuits are without merit. Medical experts remain divided, with some noting a potential link while others emphasize the risk is low and unconfirmed.

via Yahoo|

#edward-gillen #glp-1-lawsuits #health-and-legal

health10 days ago•25 min saved

Massachusetts Father Sues Novo Nordisk Over Permanent Blindness Linked to Ozempic

Edward Gillen, a 59-year-old Massachusetts father and former state highway worker, has filed a lawsuit against Novo Nordisk alleging that the diabetes drug Ozempic caused him to go permanently blind. Gillen, who took the medication for approximately a year to manage diabetes, reported sudden vision loss in May 2025 that progressed to total blindness by June 1. Doctors diagnosed him with nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition described as a 'stroke' of the optic nerve. Gillen is part of a growing wave of over 200 lawsuits in federal court against GLP-1 manufacturers, including Novo Nordisk and Eli Lilly, claiming the drugs caused irreversible vision loss without adequate warning. While Gillen’s community is raising funds for his adaptive training, Novo Nordisk maintains that the lawsuits are without merit and that semaglutide has a well-established safety profile.

via New York Post|

#glp-1 #health #lawsuit

health-and-science10 days ago•3 min saved

Novo Nordisk data shows Wegovy pill sustains weight loss after injection switch

Novo Nordisk presented real-world data indicating that patients switching from injectable obesity drugs to the new oral Wegovy pill continued losing weight. The analysis suggests the pill may offer convenience without sacrificing efficacy, potentially shifting patient preference away from weekly injections.

via CNBC|

#cagrisema #glp-1-drugs #health-and-science

health-and-pharma12 days ago•0 min saved

Novo Nordisk rebrands GLP-1s from medical treatment to lifestyle product

Novo Nordisk is shifting its marketing of GLP-1 drugs from medical necessity to lifestyle enhancement, using slogans like 'Live lighter' and referring to users as 'customers' rather than 'patients.' While these drugs offer significant weight loss and health benefits, experts warn that this consumer-focused approach ignores serious side effects, legal risks for prescribers, and the high costs that strain healthcare budgets.

via STAT|

#glp-1 #health-and-pharma #novo-nordisk

business15 days ago•6 min saved

Novo’s Capital Markets Day fails to halt Eli Lilly’s expanding obesity lead

Novo Nordisk’s recent strategy presentation failed to reassure investors, as Eli Lilly continues to widen its market share advantage in obesity treatments. While Novo outlined a broad pipeline to replace its flagship drugs, Lilly’s commercial strength and new products are driving a significant shift in market dominance.

via cnbc.com|

#business #capital-markets-day #eli-lilly

health15 days ago•25 min saved

GLP-1 Lawsuits Surge Over Rare 'Eye Stroke' Claims

Hundreds of lawsuits allege that popular weight-loss drugs like Ozempic and Mounjaro cause NAION, a rare condition leading to permanent vision loss. While manufacturers deny causation, some countries have updated drug labels to include this risk, and the FDA is reviewing the evidence.

via New York Post|

#eli-lilly #glp-1-drugs #health

health-and-legal16 days ago

GLP-1 Makers Face Hundreds of Lawsuits Over Rare, Permanent Vision Loss

Hundreds of lawsuits have been filed against Novo Nordisk and Eli Lilly, alleging that popular GLP-1 medications like Ozempic and Wegovy cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition resulting in sudden, permanent vision loss. While the drugmakers deny a causal link and cite robust safety data, plaintiffs argue the companies failed to warn patients of this risk. The FDA is currently investigating the potential connection, though medical experts note that even if a risk exists, the absolute probability remains extremely low.

via WLWT|

#eli-lilly #fda #glp-1-drugs

health17 days ago•0 min saved

GLP-1 Blindness Lawsuits Surge as Novo Nordisk, Eli Lilly Deny Causation

Hundreds of lawsuits allege that GLP-1 weight-loss and diabetes drugs like Ozempic and Mounjaro caused permanent blindness through a rare condition called NAION. While patients and attorneys report a spike in vision-loss claims this summer, drugmakers Novo Nordisk and Eli Lilly deny any causal link, citing internal studies and existing safety data. The legal battle centers on whether the companies failed to warn patients about this risk, which is noted on labels in some countries but not in the U.S.

via WSB-TV|

#eli-lilly #glp-1-drugs #health

health-and-legal17 days ago

GLP-1 Vision Loss Lawsuits Surge as NAION Claims Mount Against Eli Lilly, Novo Nordisk

Hundreds of lawsuits accuse GLP-1 manufacturers of failing to warn patients about NAION, a rare condition causing sudden vision loss. While drugmakers deny causation, plaintiffs argue labels in the U.S. lack warnings present in other countries. Experts note mixed evidence, with some studies showing a slight risk increase but emphasizing that absolute risk remains low and drug benefits often outweigh potential harms.

via AZ Family|

#eli-lilly #glp-1-drugs #health-and-legal

finance18 days ago•23 min saved

Novo Signals Higher-M&A Ambition as It Targets Five+ Obesity Blockbusters

Novo Nordisk signaled a bigger M&A push and ambitions for more than five obesity blockbusters by 2030, a plan that led to a share drop for Novo while lifting smaller obesity-focused names VKTX, GPCR and ALT on expectations of deal activity and partnerships.

via Yahoo Finance|

#alt #finance #gpcr

business18 days ago•2 min saved

Novo Nordisk Eyes M&A to Diversify Beyond GLP-1 Amid Weight-Loss Push

Novo Nordisk signaled it may pursue acquisitions to close gaps against rivals in the crowded weight‑loss market, as investors reacted skeptically to a Capital Markets Day plan. CEO Mike Doustdar said the firm aims to diversify beyond diabetes and obesity into adjacent areas and could strike deals outside its core as Wegovy’s exclusivity wanes, with a long‑range plan to launch five multi‑blockbuster drugs by 2030 and target more than 150 billion Danish kroner in sales by 2035; the stock has faced pressure amid the broader competitive landscape, including Lilly’s dominance in GLP-1 therapies.

via cnbc.com|

#business #diversification #glp-1

business18 days ago•7 min saved

Novo bets on Consumer Rx and five-blockbuster lineup amid investor pushback

At a London Capital Markets Day, Novo Nordisk outlined a Consumer Rx strategy and a plan to launch at least five multi-blockbusters by 2030, led by CagriSema (cagrilintide plus semaglutide) with assets like denecimig and zenagamtide; the push includes expanding Wegovy, broadening U.S. access, and boosting manufacturing, while cutting roughly 4,000 more jobs; investors sent the stock lower as they pressed for more detail on M&A and execution risk.

via Fierce Pharma|

#business #cagrisema #consumer-rx

finance18 days ago•20 min saved

Novo Nordisk slides on patent cliff worries after cautious growth targets

Novo Nordisk shares fell more than 7% after its Capital Markets Day failed to reassure investors about weight‑loss drug competition and looming semaglutide patent expiry, as the company projects five multi‑blockbuster drugs by 2030 and over 150 billion Danish kroner in risk‑adjusted pipeline sales by 2035, while acknowledging a CagriSema Phase 3 miss and tight competition in the obesity drug market (Lilly leads ~61% vs Novo's ~39%).

via Yahoo Finance|

#finance #novo-nordisk #obesity-drugs

health19 days ago•3 min saved

Mass. man’s sudden blindness tied to Ozempic GLP-1 therapy

Mass. resident Ed Gillen says a year on GLP-1 diabetes therapy with Ozempic led to sudden, irreversible blindness from non-arteritic anterior ischemic optic neuropathy. After symptoms began in May 2025, his vision deteriorated rapidly, ending his 39-year state job and prompting adaptive training at the Carroll Center for the Blind. He joined a consolidated federal lawsuit alleging Novo Nordisk failed to warn about the risk of optic nerve damage, though the company maintains safety studies show no increased risk.

via Boston 25 News|

#blindness #glp-1 #health